RxDoctor Payments Data

Richard Goldstein, MD

Cardiovascular Disease · Horsham, PANPI 1457342529

Payments from drug & device makers

$95in general payments, 2019–2025

Across 5 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$22
  • Novartis$21
  • E.r. Squibb & Sons, L.L.C.$21
  • Sanofi-aventis U.S. LLC$18
  • Pfizer$13

What the payments were for

  • Food & beverage$95100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$95 in reported general payments places this provider in the 5th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$245,170
Medicare patients
1,575
Services billed
3,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$403,968
XareltoRivaroxaban103$135,502
MultaqDronedarone Hcl18$31,431
EntrestoSacubitril/Valsartan21$19,470
Praluent PenAlirocumab17$12,944
Metoprolol Succinate496$7,835
Repatha SureclickEvolocumab13$7,096
Repatha SyringeEvolocumab12$6,631
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$4,844
Amiodarone Hcl112$3,371
Atorvastatin Calcium190$2,991
CrestorRosuvastatin Calcium11$2,971
Rosuvastatin Calcium164$2,842
Flecainide Acetate53$2,786
Nadolol37$2,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$403,968342 claims
Johnson & JohnsonXarelto$22$135,502103 claims
Sanofi-aventis U.S. LLCMultaq$18$31,43118 claims
NovartisEntresto$21$19,47021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Horsham

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →